Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant CIK Immunotherapy in Colon Cancer
NCT01929499Phase 2Unknown
- Start
- Sep 2013
- Primary completion
- Aug 2016
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of unmodified CIK in colon cancer (3 arms). Primary endpoint: Disease Free Survival at 5 years. Status: unknown.
02
Drugs
unmodified CIK
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT01929499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01929499.